Selective Retina Therapy Reduces Bruch's Membrane Thickness and Retinal Pigment Epithelium Pathology in Age-Related Macular Degeneration Mouse Models.
RPE morphology
drusen
dry AMD
selective retina therapy (SRT)
subthreshold laser therapy
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
14
02
2019
accepted:
03
09
2019
entrez:
19
11
2019
pubmed:
19
11
2019
medline:
19
11
2019
Statut:
epublish
Résumé
To investigate the effect of selective retina therapy (SRT) on age-related macular degeneration (AMD)-like alterations of retinal pigment epithelium (RPE) and Bruch's membrane (BrM) in AMD mouse models as therapeutic approach for the treatment of dry AMD. In B6.129P2- Nearly all ApoE SRT reduces BrM thickness and AMD-like RPE alterations in AMD mouse models without damage to structural or functional properties of neuroretina. It may be a prophylactic or therapeutic option for dry AMD. SRT shows therapeutic effectivity in murine AMD models and might therefore become an option for the treatment of dry AMD.
Identifiants
pubmed: 31737435
doi: 10.1167/tvst.8.6.11
pii: TVST-19-1436
pmc: PMC6855371
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11Informations de copyright
Copyright 2019 The Authors.
Références
J Biomed Opt. 2005 Mar-Apr;10(2):024001
pubmed: 15910075
Graefes Arch Clin Exp Ophthalmol. 2008 Oct;246(10):1373-8
pubmed: 18546010
Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2488-500
pubmed: 27159441
Transl Vis Sci Technol. 2018 May 1;7(3):2
pubmed: 29736323
Arch Ophthalmol. 2001 Oct;119(10):1439-52
pubmed: 11594943
PLoS One. 2011 Apr 29;6(4):e19456
pubmed: 21559389
Annu Rev Cell Dev Biol. 2001;17:463-516
pubmed: 11687497
Bull Soc Belge Ophtalmol. 2006;(302):51-69
pubmed: 17265790
Graefes Arch Clin Exp Ophthalmol. 2018 Sep;256(9):1639-1651
pubmed: 30056549
Exp Eye Res. 2001 Feb;72(2):137-46
pubmed: 11161729
Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2035-42
pubmed: 10892840
PLoS One. 2017 Mar 10;12(3):e0173716
pubmed: 28282423
FASEB J. 2015 Feb;29(2):696-710
pubmed: 25392267
FASEB J. 1991 May;5(8):2145-54
pubmed: 1850705
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD006537
pubmed: 19588397
Graefes Arch Clin Exp Ophthalmol. 2006 Dec;244(12):1638-45
pubmed: 16758179
J Biomed Opt. 2005 Nov-Dec;10(6):064022
pubmed: 16409087
Graefes Arch Clin Exp Ophthalmol. 2017 Feb;255(2):243-254
pubmed: 27497611
Ophthalmic Physiol Opt. 2014 Jul;34(4):390-6
pubmed: 24903538
Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1323-1331
pubmed: 29625455
Lasers Surg Med. 2000;27(5):451-64
pubmed: 11126439
Hum Mol Genet. 2003 Sep 1;12(17):2179-89
pubmed: 12915475
Arch Ophthalmol. 1992 Dec;110(12):1786-92
pubmed: 1463423
Ophthalmic Surg Lasers Imaging. 2009 Nov-Dec;40(6):530-8
pubmed: 19928717
Exp Eye Res. 2012 Apr;97(1):63-72
pubmed: 22387137
Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255(7):1375-1383
pubmed: 28421342
Ophthalmology. 2006 Apr;113(4):622.e1
pubmed: 16581422
Invest Ophthalmol Vis Sci. 2012 May 17;53(6):2921-7
pubmed: 22447858
Invest Ophthalmol Vis Sci. 2002 Feb;43(2):458-65
pubmed: 11818391
Ophthalmology. 2019 Jun;126(6):829-838
pubmed: 30244144
J Biomed Opt. 2018 Nov;23(11):1-12
pubmed: 30392199
Invest Ophthalmol Vis Sci. 1999 Feb;40(2):443-9
pubmed: 9950604
Br J Ophthalmol. 2011 Dec;95(12):1638-45
pubmed: 21890786
Graefes Arch Clin Exp Ophthalmol. 2010 Sep;248(9):1263-72
pubmed: 20393742
N Engl J Med. 2011 May 19;364(20):1897-908
pubmed: 21526923
Exp Eye Res. 1984 Feb;38(2):137-51
pubmed: 6714331
Arch Ophthalmol. 1999 Aug;117(8):1028-34
pubmed: 10448745
Invest Ophthalmol Vis Sci. 2012 Nov 27;53(12):7833-46
pubmed: 23074204
Invest Ophthalmol Vis Sci. 2016 Mar;57(3):1310-6
pubmed: 26998717
Ophthalmologe. 2006 Sep;103(9):742-8
pubmed: 16924447
J Neuroinflammation. 2015 Jan 15;12:6
pubmed: 25588310